Oral administration of a novel RORγt antagonist attenuates psoriasis-like skin lesion of two independent mouse models through neutralization of IL-17.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Targeting the IL-17 pathway represents a highly effective strategy for the treatment of psoriasis, using antibodies against IL-17A and IL-17 receptor, suggesting that Th17 cells essentially contribute to development of psoriasis. Th17 differentiation depends on the key transcription factor, RORγt.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Dermatol. Sci.

Title: Journal of dermatological science

Publisher: Elsevier BV

ISSN (Electronic): 1873-569X

ISSN (Print): 0923-1811

Publication date (Electronic): Jan 2017

Volume: 85

Issue: 1

Affiliations

[1 ] Department of Dermatology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.

[2 ] Frontier Research Laboratories, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan.

[3 ] Medicinal Chemistry Research Laboratories, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan.

[4 ] Department of Dermatology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan. Electronic address: sano.derma@kochi-u.ac.jp.

Article

Publisher Item ID: S0923-1811(16)30842-8

DOI: 10.1016/j.jdermsci.2016.10.001

PubMed ID: 27726924

SO-VID: b697c929-f943-4c90-8256-a1601991517b

History

Keywords: Antagonist,Mouse model,Psoriasis,RORγt,Th17

Data availability:

Keywords: Antagonist, Mouse model, Psoriasis, RORγt, Th17

Comments

Comment on this article

scite_

Cited by 14

See all cited by

- Version 1